Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A - Eckhardt, CL; Menke, LA; van Ommen, CH (J Thromb Haemost, 2009)
et al.